Inhalation Sciences Sweden Balance Sheet Health
Financial Health criteria checks 6/6
Inhalation Sciences Sweden has a total shareholder equity of SEK13.0M and total debt of SEK1.1M, which brings its debt-to-equity ratio to 8.4%. Its total assets and total liabilities are SEK18.2M and SEK5.2M respectively.
Key information
8.4%
Debt to equity ratio
SEK 1.09m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 7.83m |
| Equity | SEK 12.95m |
| Total liabilities | SEK 5.21m |
| Total assets | SEK 18.17m |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: ISAB's short term assets (SEK15.8M) exceed its short term liabilities (SEK4.8M).
Long Term Liabilities: ISAB's short term assets (SEK15.8M) exceed its long term liabilities (SEK442.0K).
Debt to Equity History and Analysis
Debt Level: ISAB has more cash than its total debt.
Reducing Debt: ISAB's debt to equity ratio has reduced from 55.2% to 8.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ISAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ISAB has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 1.5% each year.